DNLI — Denali Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $2.20bn
- $1.16bn
- $330.53m
- 56
- 25
- 49
- 39
Annual cashflow statement for Denali Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -198 | 71.1 | -291 | -326 | -145 |
| Depreciation | |||||
| Non-Cash Items | 33.9 | 50.4 | 94 | 94.9 | 60.4 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 4.17 | 286 | -23.4 | -24 | -290 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -152 | 416 | -211 | -245 | -358 |
| Capital Expenditures | -17.9 | -3.1 | -8.5 | -17.8 | -12.9 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 166 | -620 | -13.1 | -124 | 262 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 148 | -623 | -21.6 | -141 | 249 |
| Financing Cash Flow Items | 0 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 6.19 | 635 | 19.3 | 311 | 17.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2.33 | 428 | -214 | -75.4 | -90.9 |